At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Novo-Nordisk AS (Symbol: NVO) was held by 9 of these ...

In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $81 per share. By comparison ...

NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...

Novo Nordisk A/S (NVO) stock price is 84.45 and Novo Nordisk A/S (NVO) 10-day simple moving average is 83.59. Novo Nordisk A/S (NVO) stock price is 84.45 and Novo Nordisk A/S (NVO) 50-day simple ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Private equity-backed Infinity Natural Resources raised $265 million on Thursday in its initial public offering in the U.S., the latest first-time share sale by an energy company in New York in recent ...

Metsera (MTSR) hopes to list its shares on Nasdaq under the symbol MTSR. Lead bookrunners ... Other GLP-1 receptor agonist drugs for obesity include Novo Nordisk's (NVO) Wegovy and Eli Lilly's ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR) said it was ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Looking at options history for Novo Nordisk NVO we detected 8 trades. If we consider the specifics of each trade, it is ...